MedTrace Logo

DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence

NCT03397771 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2020-06-11

Study results available
· View outcomes & findings →

Summary

This study will explore the safety, tolerability and efficacy of litoxetine in men and women who suffer from urinary incontinence

Conditions

Interventions

DRUG

Litoxetine

oral study medication provided in a dose titration manner

DRUG

placebo

placebo medication provided in a dose titration manner

Sponsors & Collaborators

  • Ixaltis SA

    lead INDUSTRY

Principal Investigators

  • E Svanberg · Ixaltis SA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-03
Primary Completion
2019-05-30
Completion
2019-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03397771 on ClinicalTrials.gov